Belgian radioisotope producer secures US$104.1 million to expand global production
Deal Flash
PanTera, the Belgian radioisotope producer, has completed a US$104.1 million (€93 million) Series A fundraise, which was led by EQT Life Sciences and oversubscribed. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round also included Kurma Partners, Eurazeo, Korys, Paladin and PMV.
PanTera, an IBA and SCK CEN joint venture, aims to achieve the large-scale production of Actinium-225 ( 225Ac), one of the most promising alpha-emitting radioisotopes for fighting cancer. The funds raised will be used primarily to support the construction of a state-of-the-art production facility in Belgium. This facility will not only be able to produce the radioisotope on a mass scale, but will also help fulfill PanTera’s ultimate goal of improving the accessibility of future, innovative cancer therapy based on 225Ac and theranostics.
Oaklins KBC Securities helped us secure the necessary capital to accelerate the large- scale production of Actinium-225, which is crucial to enable a new class of targeted cancer treatments. Oaklins KBC Securities supported us in all stages of the process, from marketing the equity story and engaging with world- renowned investors in the life sciences space, to leveraging its expertise in negotiating the binding term sheet and closing the deal. This resulted in the oversubscribed US$104.1 million (€93 million) round — Belgium’s largest Series A in life sciences to date — led by EQT Life Sciences, one of the world’s largest healthcare investors. The close collaboration between management and Oaklins KBC Securities helped us get successfully through all stages of the process, making the transaction a great success in the end.SVEN VAN DEN BERGHE, CEO, PANTERA, BELGIUM
Oaklins assisted in finding a suitable investor
Oaklins’ team in Belgium acted as the sole financial advisor in this transaction. It highlights Oaklins’ experience across a range of financial ventures and growth strategies, and its expertise in identifying viable partnerships and collaborations.
Talk to our advisors
Managing Director
View profile
Managing Director
View profile
Read more about the transaction, market trends, deal drivers and M&A valuation aspects
